Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 9/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | GAPDH | P04406 | 1/20 | 0.39 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.38 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.38 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.38 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27514476 | 1.00 | MAPT (0.53) | MAPTALDH1A1POLBMEN1USP2 | |
| SCHEMBL7746169 | 1.00 | MAPT (0.53) | MAPTALDH1A1POLBMEN1USP2 | |
| SCHEMBL11075412 | 1.00 | MAPT (0.53) | MAPTALDH1A1POLBMEN1USP2 | |
| SCHEMBL308251 | 1.00 | MAPT (0.53) | MAPTALDH1A1POLBMEN1USP2 | |
| SCHEMBL28604390 | 0.85 | MAPT (0.57) | MAPTALDH1A1POLBMEN1USP2 | |
| SCHEMBL10182003 | 0.85 | MAPT (0.50) | MAPTALDH1A1POLBMEN1USP2 | |
| SCHEMBL4625578 | 0.85 | MAPT (0.50) | MAPTALDH1A1POLBMEN1USP2 | |
| SCHEMBL29090809 | 0.84 | MAPT (0.52) | MAPTALDH1A1POLBMEN1USP2 | |
| SCHEMBL8512700 | 0.83 | MAPT (0.55) | MAPTALDH1A1POLBMEN1USP2 | |
| SCHEMBL9137960 | 0.83 | MAPT (0.55) | MAPTALDH1A1POLBMEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093380-B2 | Viricides, antitumor agents, anticancer agents | PHARMASSET, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20040082574-A1 | Compounds with the bicyclo[4.2.1]nonane system for the treatment of flavivridae infections | PHARMASSET, INC. | 2004-04-29 | — | — | US | disclosed |
| EP-0708781-B1 | A 3 ADENOSINE RECEPTOR AGONISTS | USA (US) | 2001-10-04 | — | — | EP | disclosed |
| US-5773423-A | XANTHINE RIBOSIDES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-06-30 | — | — | US | disclosed |
| EP-0708781-A1 | A 3 ADENOSINE RECEPTOR AGONISTS | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 1996-05-01 | — | — | EP | disclosed |
| WO-1995002604-A1 | A3 ADENOSINE RECEPTOR AGONISTS | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082574-A1 | Compounds with the bicyclo[4.2.1]nonane system for the treatment of flavivridae infections | CYP4B1, HAVCR2, CYP2S1 | MAPT 3805/4885ALDH1A1 1212/4885POLB 3590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.